{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:44:55Z","timestamp":1789155895590,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T00:00:00Z","timestamp":1545955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for <jats:italic toggle=\"yes\">de novo<\/jats:italic> steatosis during chemotherapy for non\u2010Hodgkin lymphoma (NHL). In this retrospective case\u2010control study, adult patients with NHL were treated with rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine (R\u2010CHOP) or R\u2010CHOP + etoposide (EPOCH\u2010R). Patients with liver disease or steatosis were excluded. Abdominal computed tomography was performed pretreatment and at 3\u2010 to 6\u2010month intervals and reviewed for steatosis. Patients with <jats:italic toggle=\"yes\">de novo<\/jats:italic> steatosis were matched 1:1 to controls by age, sex, and ethnicity. Of 251 treated patients (median follow\u2010up 53 months), 25 (10%) developed <jats:italic toggle=\"yes\">de novo<\/jats:italic> steatosis, with the vast majority (23 of 25; 92%) developing it after chemotherapy. Of those, 14 (61%) developed steatosis within the first 18 months posttreatment and 20 (87%) within 36 months. Cases had higher baseline body mass index (BMI; mean\u00a0\u00b1\u00a0SD, 29.0\u00a0\u00b1\u00a06.5 versus 26.0\u00a0\u00b1\u00a05.2 kg\/m<jats:sup>2<\/jats:sup>; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.014) and hyperlipidemia (12% versus 2%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.035). Although their weights did not change during chemotherapy, BMI in cases increased by 2.4\u00a0\u00b1\u00a02 kg\/m<jats:sup>2 <\/jats:sup>(mean\u00a0\u00b1\u00a0SD) from end of treatment to steatosis compared to 0.68\u00a0\u00b1\u00a01.4 in controls (<jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.003). Etoposide\u2010containing regimens were associated with a shorter time to steatosis (median 34 weeks versus 154 weeks; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001) despite similar baseline risk factors. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> The recovery period from NHL chemotherapy appears to be a \u201chot spot\u201d for development of fatty liver, driven by early posttreatment weight gain, especially in subjects with baseline risk factors.<\/jats:p>","DOI":"10.1002\/hep4.1304","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T16:05:50Z","timestamp":1546013150000},"page":"220-226","source":"Crossref","is-referenced-by-count":10,"title":["Development of Hepatic Steatosis After Chemotherapy for Non\u2010Hodgkin Lymphoma"],"prefix":"10.1097","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-0903","authenticated-orcid":false,"given":"Gil","family":"Ben\u2010Yakov","sequence":"first","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawwa","family":"Alao","sequence":"additional","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"},{"name":"Department of Gastroenterology,Louis Stokes VA Medical Center,Cleveland,OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Haydek","sequence":"additional","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Fryzek","sequence":"additional","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ho","family":"Cho","sequence":"additional","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"},{"name":"Department of Medicine,MedStar Washington Hospital Center,Washington,DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hemmati","sequence":"additional","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"},{"name":"Department of Medicine,MedStar Health,Baltimore,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Samala","sequence":"additional","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Shovlin","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research,National Cancer Institute, National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research,National Cancer Institute, National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham","family":"Wilson","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research,National Cancer Institute, National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Jones","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences,National Institutes of Health Clinical Center,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-8216","authenticated-orcid":false,"given":"Yaron","family":"Rotman","sequence":"additional","affiliation":[{"name":"Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,12,28]]},"reference":[{"key":"hep41304-bib-0001-20240114","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.29247","article-title":"How healthy are the \u201cHealthy volunteers\u201d? Penetrance of NAFLD in the biomedical research volunteer pool","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep41304-bib-0002-20240114","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3748\/wjg.v24.i14.1491","article-title":"Nonalcoholic fatty liver disease and liver transplantation\u2010where do we stand?","volume":"24","year":"2018","journal-title":"World J Gastroenterol"},{"key":"hep41304-bib-0003-20240114","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cld.2017.08.011","article-title":"The role of nonalcoholic fatty liver disease on cardiovascular manifestations and outcomes","volume":"22","year":"2018","journal-title":"Clin Liver Dis"},{"key":"hep41304-bib-0004-20240114","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41304-bib-0005-20240114","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long\u2010term follow\u2010up of patients with NAFLD and elevated liver enzymes","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep41304-bib-0006-20240114","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long\u2010term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep41304-bib-0007-20240114","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17425255.2017.1246534","article-title":"Drug\u2010induced steatohepatitis","volume":"13","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"hep41304-bib-0008-20240114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00534-008-0016-z","article-title":"Patterns of chemotherapy\u2010induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases","volume":"16","year":"2009","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"hep41304-bib-0009-20240114","first-page":"815105","article-title":"Liver injury induced by anticancer chemotherapy and radiation therapy","volume":"2013","year":"2013","journal-title":"Int J Hepatol"},{"key":"hep41304-bib-0010-20240114","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cld.2013.07.012","article-title":"Drug\u2010induced steatohepatitis","volume":"17","year":"2013","journal-title":"Clin Liver Dis"},{"key":"hep41304-bib-0011-20240114","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","year":"2014","journal-title":"World J Gastroenterol"},{"key":"hep41304-bib-0012-20240114","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00330-011-2349-2","article-title":"Specificity of unenhanced CT for non\u2010invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis","volume":"22","year":"2012","journal-title":"Eur Radiol"},{"key":"hep41304-bib-0013-20240114","first-page":"E70","article-title":"Diagnostic criteria and clinical outcomes in sarcopenia research: A literature review","volume":"7.pii","year":"2018","journal-title":"J Clin Med"},{"key":"hep41304-bib-0014-20240114","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep41304-bib-0015-20240114","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep41304-bib-0016-20240114","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0034-1375957","article-title":"Drug\u2010induced liver injury due to cancer chemotherapeutic agents","volume":"34","year":"2014","journal-title":"Semin Liver Dis"},{"key":"hep41304-bib-0017-20240114","first-page":"168905","article-title":"Drug induced steatohepatitis: an uncommon culprit of a common disease","volume":"2015","year":"2015","journal-title":"Biomed Res Int"},{"key":"hep41304-bib-0018-20240114","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.acra.2005.02.010","article-title":"Effects of oral 5\u2010fluorouracil drugs on hepatic fat content in patients with colon cancer","volume":"12","year":"2005","journal-title":"Acad Radiol"},{"key":"hep41304-bib-0019-20240114","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90\u2010day mortality after surgery for hepatic colorectal metastases","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"hep41304-bib-0020-20240114","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ejso.2014.07.040","article-title":"Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre\u2010operative chemotherapy","volume":"40","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"hep41304-bib-0021-20240114","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1467-789X.2010.00805.x","article-title":"Weight gain in breast cancer survivors: prevalence, pattern and health consequences","volume":"12","year":"2011","journal-title":"Obes Rev"},{"key":"hep41304-bib-0022-20240114","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.2003.06.131","article-title":"Obesity in adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"hep41304-bib-0023-20240114","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/10428194.2011.619606","article-title":"Obesity in adult lymphoma survivors","volume":"53","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"hep41304-bib-0024-20240114","doi-asserted-by":"crossref","first-page":"14418","DOI":"10.1074\/jbc.M115.643015","article-title":"Regulation of hepatic cholesteryl ester transfer protein expression and reverse cholesterol transport by inhibition of DNA topoisomerase II","volume":"290","year":"2015","journal-title":"J Biol Chem"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep4.1304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/02009842-201902000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T16:09:09Z","timestamp":1705248549000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02009842-201902000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,28]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1304","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,28]]}}}